Jun 14, 2022 / 08:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone. Thanks for joining us. Pleased to have the Denali team with us. We have Ryan Watts, CEO, Co-Founder and President; and Alex Schuth, CFO and COO.
Ryan, to start here, you've made steady progress with the pipeline, notably with positive data from Hunter Syndrome with your blood brain-barrier portfolio, and we saw some data at World Symposium recently. As you look to second half onwards, where do you see the most important areas that investors should focus to understand the value proposition for the story?
Ryan J. Watts - Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Well, thank you for having us here again, Salveen. And yes, it's been a lot of steady progress. In fact, we founded Denali 7 years ago. And I think what's most exciting for us right now is that we have 6 clinical stage programs, and 3 of them are entering late-stage efficacy studies or have entered within the last several months. And I think that just shows the early
Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers